Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of ...

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

In preliminary Phase 1b/2a results released in January, the highest dose of the once-weekly injection led to 22% weight loss measured at 36 weeks. Last month, Metsera raised $275 million from its ...

The data showed that MET-097i helped participants lose weight, with some shedding up ... so far, limited. Metsera is also one of the 10 stocks insiders spent the most money on recently.

Guggenheim has initiated Metsera at buy saying that the ... excellent 12-week weight loss seen in a phase 2a trial, and an improved tolerability profile. "If 097i demonstrates acceptable ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Metsera, Inc. (NASDAQ ... the potential to address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health Partners ...

A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...

Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in ...